Ruxolitinib for Therapy of Graft-versus-Host Disease

Objective: Steroid-resistant graft-versus-host disease (GvHD) is a major challenge after allogeneic stem cell transplantation and associated with significant morbidity and mortality. There is no therapeutic standard defined beyond calcineurin inhibitors (CNI) and steroids. Furthermore, some patients...

Full description

Bibliographic Details
Published in:BioMed research international, Vol. 2019 (2019), p. 8163780
Main Author: Neumann, Thomas
Other Involved Persons: Schneidewind, Laila ; Weigel, Martin ; Plis, Andrzej ; Vaizian, Rem ; Schmidt, Christian A ; Krüger, William
Format: electronic Article
Language:English
ISSN:2314-6141
Item Description:Date Completed 22.07.2019
Date Revised 22.07.2019
published: Electronic-eCollection
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description:Online-Ressource
DOI:10.1155/2019/8163780
Subjects:
QR Code: Show QR Code